Veraxa Biotech Holding AG (VRXA) Form 6-K — Jul 27, 2026

Veraxa Biotech AG announced the advancement of its bispecific antibody drug conjugate program VXA-222 following the successful achievement of a key technical milestone in its collaboration with OmniAb. The program moves into its next phase with OmniAb’s discovery work now concluded, allowing Veraxa to apply its proprietary linker technology and conjugation expertise to establish a lead candidate for solid tumor indications.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.